Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

CAMMS223 Trial Investigators

Research output: Contribution to journalArticlepeer-review

759 Scopus citations

Fingerprint

Dive into the research topics of 'Alemtuzumab vs. interferon beta-1a in early multiple sclerosis'. Together they form a unique fingerprint.

Medicine & Life Sciences